Tagworks Pharmaceuticals Announce FDA Clearance and New CMO Appointment

Tagworks Pharmaceuticals has announced the clearance by the FDA of their IND application, allowing them to initiate a Phase 1 clinical trial for their drug candidate TGW101. This marks a pivotal step in the clinical development of TGW101, indicating potential advancements in therapeutic treatments. Concurrently, Tagworks has bolstered its leadership team with the appointment of Dr. Keith Orford as Chief Medical Officer. Dr. Orford's expertise and experience are expected to significantly contribute to the firm's strategic direction, particularly in the areas of clinical development and regulatory affairs. The developments come under the backing of Ysios Capital, which supports the company’s innovative approaches and contributes to its growth in the biotech sector.